Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2011

01-09-2011 | Brief Report

Two patients with germline mutations in both BRCA1 and BRCA2 discovered unintentionally: a case series and discussion of BRCA testing modalities

Authors: Ann Marie Augustyn, Nicole M. Agostino, Tara L. Namey, Suresh Nair, Martin A. Martino

Published in: Breast Cancer Research and Treatment | Issue 2/2011

Login to get access

Abstract

When a family is known to have a BRCA mutation, genetic testing for family members is typically limited to single site analysis of the known mutation. The exception to this is in Ashkenazi Jewish families, where testing for the three common Ashkenazi Jewish BRCA mutations is recommended. We report two cases, one without Ashkenazi Jewish ancestry and one with maternal Ashkenazi Jewish ancestry, who underwent Comprehensive BRACAnalysis testing despite known BRCA1 mutations in family members. Testing identified the BRCA1 mutation previously identified, and a second mutation in BRCA2. These cases raise the question of whether or not Single Site BRACAnalysis for a known familial BRCA mutation is always the appropriate test when testing an affected individual. The implications of missing a second mutation are discussed.
Literature
1.
go back to reference Ramus SJ, Friedman LS, Gayther SA et al (1997) A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2. Nat Genet 15:14–15PubMedCrossRef Ramus SJ, Friedman LS, Gayther SA et al (1997) A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2. Nat Genet 15:14–15PubMedCrossRef
2.
go back to reference Leegte B, van der Hout AH, Deffenbaugh AM et al (2005) Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations. J Med Genet 42:e20PubMedCrossRef Leegte B, van der Hout AH, Deffenbaugh AM et al (2005) Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations. J Med Genet 42:e20PubMedCrossRef
3.
go back to reference Martin M, Ford C, Burbidge LA, Deffenbaugh A, et al. Myriad Genetic Laboratories, Inc Salt Lake City, UT. Poster Presentation at American Society of Human Genetics 56th Annual Meeting. October 9–13. New Orleans, LA Martin M, Ford C, Burbidge LA, Deffenbaugh A, et al. Myriad Genetic Laboratories, Inc Salt Lake City, UT. Poster Presentation at American Society of Human Genetics 56th Annual Meeting. October 9–13. New Orleans, LA
4.
go back to reference Friedman E, Bar-Sade Bruchim R, Kruglikova A et al (1998) Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. Am J Hum Genet 63:1224–1227PubMedCrossRef Friedman E, Bar-Sade Bruchim R, Kruglikova A et al (1998) Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. Am J Hum Genet 63:1224–1227PubMedCrossRef
5.
go back to reference Randall TC, Bell KA, Rebane BA et al (1998) Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient. Gynecol Oncol 70(3):432–434PubMedCrossRef Randall TC, Bell KA, Rebane BA et al (1998) Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient. Gynecol Oncol 70(3):432–434PubMedCrossRef
6.
go back to reference Moslehi R, Russo D, Phelan C et al (2000) An unaffected individual from a breast/ovarian cancer family with germline mutations in both BRCA1 and BRCA2. Clin Genet 57(1):70–73PubMedCrossRef Moslehi R, Russo D, Phelan C et al (2000) An unaffected individual from a breast/ovarian cancer family with germline mutations in both BRCA1 and BRCA2. Clin Genet 57(1):70–73PubMedCrossRef
7.
go back to reference Bell DW, Erban J, Sgroi DC et al (2002) Selective loss of heterozygosity in multiple breast cancer from a carrier of mutation in both BRCA1 and BRCA2. Cancer Res 62:2741–2743PubMed Bell DW, Erban J, Sgroi DC et al (2002) Selective loss of heterozygosity in multiple breast cancer from a carrier of mutation in both BRCA1 and BRCA2. Cancer Res 62:2741–2743PubMed
8.
go back to reference Tsongalis G, Linfer D, Johnson R et al (1998) Double heterozygosity for mutations in BRCA1 and BRCA2 in a breast cancer patient. Arch Pathol Lab Med 122:548–550PubMed Tsongalis G, Linfer D, Johnson R et al (1998) Double heterozygosity for mutations in BRCA1 and BRCA2 in a breast cancer patient. Arch Pathol Lab Med 122:548–550PubMed
9.
go back to reference Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10, 000 individuals. J Clin Oncol 20:1480–1490PubMedCrossRef Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10, 000 individuals. J Clin Oncol 20:1480–1490PubMedCrossRef
12.
go back to reference Peto J, Collins N, Barfoot R et al (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943–949PubMedCrossRef Peto J, Collins N, Barfoot R et al (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943–949PubMedCrossRef
13.
go back to reference Loader S, Rowley PT (1998) Deleterious mutation of both BRCA1 and BRCA2 in three siblings. Genet Test 2:75–77PubMedCrossRef Loader S, Rowley PT (1998) Deleterious mutation of both BRCA1 and BRCA2 in three siblings. Genet Test 2:75–77PubMedCrossRef
14.
go back to reference Tesoriero A, Anderson C, Southey M et al (1999) De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation. Am J Hum Genet 65:567–569PubMedCrossRef Tesoriero A, Anderson C, Southey M et al (1999) De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation. Am J Hum Genet 65:567–569PubMedCrossRef
15.
go back to reference Liede A, Rehal P, Vesprini D et al (1998) A breast cancer patient of Scottish descent with germ-line mutations in BRCA1 and BRCA2. Am J Hum Genet 62:1543–1544PubMedCrossRef Liede A, Rehal P, Vesprini D et al (1998) A breast cancer patient of Scottish descent with germ-line mutations in BRCA1 and BRCA2. Am J Hum Genet 62:1543–1544PubMedCrossRef
16.
go back to reference Caldes T, De la Hoya M, Tosar A, Sulleiro S, Godino J, Ibanez D, Martin M, Perez-Segura P, Diaz-Rubio E (2002) A breast cancer family from Spain with germline mutation in both BRCA1 and BRCA2 genes. J Med Genet 39(8):e44PubMedCrossRef Caldes T, De la Hoya M, Tosar A, Sulleiro S, Godino J, Ibanez D, Martin M, Perez-Segura P, Diaz-Rubio E (2002) A breast cancer family from Spain with germline mutation in both BRCA1 and BRCA2 genes. J Med Genet 39(8):e44PubMedCrossRef
17.
go back to reference Musolino A, Naldi N, Michiara M et al (2005) A breast cancer family from Italy with germline mutations in both the BRCA1 and BRCA2 genes. Breast Cancer Res Treat 91:203–205PubMedCrossRef Musolino A, Naldi N, Michiara M et al (2005) A breast cancer family from Italy with germline mutations in both the BRCA1 and BRCA2 genes. Breast Cancer Res Treat 91:203–205PubMedCrossRef
18.
go back to reference Smith M, Fawcett S, Sigalas E, Bell R, Devery S, Andrieska N, Winship I (2008) Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes. Fam Cancer 7:119–124PubMedCrossRef Smith M, Fawcett S, Sigalas E, Bell R, Devery S, Andrieska N, Winship I (2008) Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes. Fam Cancer 7:119–124PubMedCrossRef
19.
go back to reference Zuradelli M, Peissel B, Monoukian S et al (2010) Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics. Breast Cancer Res Treat 124:251–258PubMedCrossRef Zuradelli M, Peissel B, Monoukian S et al (2010) Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics. Breast Cancer Res Treat 124:251–258PubMedCrossRef
20.
go back to reference Cremin C, Wong N, Buzaglo K, Paradis A, Foulkes W (2002) Nonovarian pelvic cancers in BRCA1/2 mutation carriers and the BRCAPRO statistical model. J Clin Oncol 20:3936–3937PubMedCrossRef Cremin C, Wong N, Buzaglo K, Paradis A, Foulkes W (2002) Nonovarian pelvic cancers in BRCA1/2 mutation carriers and the BRCAPRO statistical model. J Clin Oncol 20:3936–3937PubMedCrossRef
21.
go back to reference Choi DH, Lee MH, Ball AE, Carter D, Haffty B (2004) Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol 22:1638–1645PubMedCrossRef Choi DH, Lee MH, Ball AE, Carter D, Haffty B (2004) Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol 22:1638–1645PubMedCrossRef
22.
go back to reference Choi DH, Lee MH, Haffty B (2006) Double heterozygotes for Non-Caucasian families with mutations in BRCA-1 and BRCA-2 Genes. Breast J 12:216–220PubMedCrossRef Choi DH, Lee MH, Haffty B (2006) Double heterozygotes for Non-Caucasian families with mutations in BRCA-1 and BRCA-2 Genes. Breast J 12:216–220PubMedCrossRef
23.
go back to reference Pal T, Purmuth-Wey J, Betts JA et al (2005) BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104:2807–2816PubMedCrossRef Pal T, Purmuth-Wey J, Betts JA et al (2005) BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104:2807–2816PubMedCrossRef
24.
go back to reference Myriad Genetic Laboratories, Inc. Services and Price List. April 2010 Myriad Genetic Laboratories, Inc. Services and Price List. April 2010
25.
go back to reference Lu K, Kauff N, Powell CB et al (2009) ACOG Practice Bulletin: hereditary breast and ovarian cancer syndrome. Obstet Gynecol 113:957–966 Lu K, Kauff N, Powell CB et al (2009) ACOG Practice Bulletin: hereditary breast and ovarian cancer syndrome. Obstet Gynecol 113:957–966
27.
go back to reference National Comprehensive Cancer Network, “Genetic/Familial High-Risk Assessment: Breast and Ovarian,” November 2010. http://www.nccn.org. Accessed 12 Dec 2010 National Comprehensive Cancer Network, “Genetic/Familial High-Risk Assessment: Breast and Ovarian,” November 2010. http://​www.​nccn.​org. Accessed 12 Dec 2010
29.
go back to reference Offit K, Levran O, Mullaney B et al (2003) Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 95:1548–1551PubMed Offit K, Levran O, Mullaney B et al (2003) Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 95:1548–1551PubMed
30.
go back to reference Thompson D, Easton DF (2002) Cancer incidence in BRCA1 Mutation Carriers. J Natl Cancer Inst 94:1358–1365PubMed Thompson D, Easton DF (2002) Cancer incidence in BRCA1 Mutation Carriers. J Natl Cancer Inst 94:1358–1365PubMed
31.
go back to reference Levine DA, Argenta PA, Yee CJ et al (2003) Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 21:4222–4227PubMedCrossRef Levine DA, Argenta PA, Yee CJ et al (2003) Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 21:4222–4227PubMedCrossRef
32.
go back to reference Abeloff MD, Armitage JO, Niederhuber JE et al (2008) Abeloff’s clinical oncology, 4th edn. Churchill Livingstone Elsevier, PA Abeloff MD, Armitage JO, Niederhuber JE et al (2008) Abeloff’s clinical oncology, 4th edn. Churchill Livingstone Elsevier, PA
33.
go back to reference Devita VT Jr, Hellman S, Rosenberg SA et al (2008) Cancer principle and practice of oncology, 8th edn. Lippincott Williams and Wilkins, PA Devita VT Jr, Hellman S, Rosenberg SA et al (2008) Cancer principle and practice of oncology, 8th edn. Lippincott Williams and Wilkins, PA
34.
go back to reference The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310–1316CrossRef The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310–1316CrossRef
Metadata
Title
Two patients with germline mutations in both BRCA1 and BRCA2 discovered unintentionally: a case series and discussion of BRCA testing modalities
Authors
Ann Marie Augustyn
Nicole M. Agostino
Tara L. Namey
Suresh Nair
Martin A. Martino
Publication date
01-09-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1597-9

Other articles of this Issue 2/2011

Breast Cancer Research and Treatment 2/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine